

Gennaro Giustino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4981545/publications.pdf>

Version: 2024-02-01

104
papers

4,972
citations

136740

32
h-index

98622

67
g-index

106
all docs

106
docs citations

106
times ranked

6281
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	1.0	92
2	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 20-29.	1.0	8
3	Using Clinical and Echocardiographic Characteristics to Characterize the Risk of Ischemic Stroke in Patients with COVID-19. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106217.	0.7	6
4	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	0.7	4
5	Left Ventricular Thrombus Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1010-1022.	1.2	53
6	Re-analysis of the effect of coronary artery bypass surgery in patients with left ventricular dysfunction. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	0
7	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
8	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1407-1425.	1.2	21
9	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	1.4	2
10	Coronary In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 348-372.	1.2	72
11	Biventricular strain by speckle tracking echocardiography in COVID-19: findings and possible prognostic implications. <i>Future Cardiology</i> , 2021, 17, 663-667.	0.5	28
12	Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1504-1511.	0.4	7
13	Trends in MitraClip, mitral valve repair, and mitral valve replacement from 2000 to 2016. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 551-562.e4.	0.4	28
14	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	1.4	40
15	Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 713-724.	1.2	21
16	Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. <i>ESC Heart Failure</i> , 2021, 8, 1047-1054.	1.4	28
17	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. <i>Cardiovascular Diabetology</i> , 2021, 20, 10.	2.7	12
18	Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009879.	1.4	33

#	ARTICLE	IF	CITATIONS
19	Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E222-E234.	0.7	17
20	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 521-534.	0.5	3
21	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E785-E795.	0.7	2
22	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
23	Echocardiography in the time of Covid-19: Ultrasound enhancing agents save time and augment diagnostic information. <i>International Journal of Cardiology</i> , 2021, 346, 100-102.	0.8	0
24	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2447-2457.	1.1	3
25	Periprocedural myocardial infarction: multiple definitions and still a quest for consensus. <i>European Heart Journal</i> , 2021, , .	1.0	1
26	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	0.7	5
27	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	13.9	362
28	Impact of Aortic Atherosclerosis Burden on Outcomes of Surgical Aortic Valve Replacement. <i>Annals of Thoracic Surgery</i> , 2020, 109, 465-471.	0.7	9
29	Malignant Arrhythmias in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008920.	2.1	57
30	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1999-2010.	1.2	23
31	Trimming the need for invasive ventilation: pragmatic critical care during the COVID-19 pandemic. <i>BMJ Case Reports</i> , 2020, 13, e237597.	0.2	0
32	NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2317-2328.	1.1	33
33	Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2011-2023.	1.2	165
34	Characterization of Myocardial Injury in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2043-2055.	1.2	303
35	Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, e66.	13.9	7
36	Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19. <i>Circulation: Heart Failure</i> , 2020, 13, e007485.	1.6	89

#	ARTICLE	IF	CITATIONS
37	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions, 2020, 13, 1417-1428.	1.1	77
38	Standard Versus Ultrasound-Guided Cannulation of the Femoral Artery in Patients Undergoing Invasive Procedures: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2020, 9, 677.	1.0	25
39	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	1.4	21
40	Reconciling the evidence on the treatment of left main coronary artery disease. International Journal of Cardiology, 2020, 311, 15-17.	0.8	1
41	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. JACC: Cardiovascular Interventions, 2020, 13, 375-387.	1.1	55
42	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	0.7	1
43	Ticagrelor With or Without Aspirin After Complex PCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122
44	Abstract 15808: Relationship Between Myocardial Injury, Wall Motion Abnormalities and Mortality in Patients With Covid-19: The Circ-19 Registry. Circulation, 2020, 142, .	1.6	0
45	Abstract 15096: Electrocardiographic QRS Amplitude Predicts Mortality in Hospitalized Patients With CoViD-19. Circulation, 2020, 142, .	1.6	0
46	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	1.4	6
47	Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Aortic Mitral Regurgitation. JACC: Heart Failure, 2019, 7, 481-490.	1.9	37
48	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	0.8	8
49	Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. CardioRenal Medicine, 2019, 9, 160-167.	0.7	13
50	Incidence and Risk Factors for Permanent Pacemaker Implantation Following Mitral or Aortic Valve Surgery. Journal of the American College of Cardiology, 2019, 74, 2607-2620.	1.2	51
51	Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. Journal of Clinical Medicine, 2019, 8, 2016.	1.0	5
52	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	0.8	4
53	Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2019, 12, 733-741.	2.3	17
54	Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Gut and Liver, 2019, 13, 54-61.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Antithrombotic Treatment after Transcatheter Heart Valves Implant. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 038-045.	1.5	22
56	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1997-2005.	1.8	19
57	Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 453-461.	1.3	5
58	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.	1.2	59
59	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. <i>International Journal of Cardiology</i> , 2018, 268, 61-67.	0.8	46
60	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	0.7	19
61	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1277-1286.	1.1	14
62	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , 2017, 184, 81-87.	1.2	95
63	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 1166-1172.	0.7	12
64	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3055-3066.	1.2	117
65	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.	1.1	17
66	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.	1.2	58
67	Bioresorbable Vascular Scaffolds in Women. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1891-1893.	1.1	1
68	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>International Journal of Cardiology</i> , 2017, 246, 20-25.	0.8	15
69	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents) <i>TJ ETQq1 1 0.78431417 BT /Over</i>	0.7	13
70	Ischemia-reperfusion injury and ischemic postconditioning in acute myocardial infarction: Lost in translation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1068-1069.	0.7	13
71	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
72	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	0.7	13

#	ARTICLE	IF	CITATIONS
73	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	1.1	41
74	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	1.1	54
75	Efficacy and safety of routine thrombus aspiration in patients with <scp>ST</scp>-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2016, 87, 650-660.	0.7	12
76	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	0.7	18
77	Natural History, Diagnostic Approaches, and Therapeutic Strategies for Patients With Asymptomatic Severe Aortic Stenosis. Journal of the American College of Cardiology, 2016, 67, 2263-2288.	1.2	198
78	â€œCapturingâ€ the Benefits of Dual-Therapy Stent Technology. JACC: Cardiovascular Interventions, 2016, 9, 1135-1137.	1.1	4
79	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	1.1	51
80	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	1.2	445
81	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	1.2	319
82	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	20
83	Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). American Journal of Cardiology, 2016, 118, 1097-1104.	0.7	17
84	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	1.1	32
85	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	1.1	37
86	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2124-2133.	1.1	58
87	One-year results of the <scp>ICON</scp> (ionic versus non-ionic contrast to obviate worsening) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 62 Cardiovascular Interventions, 2016, 87, 703-709.	0.7	9
88	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	1.1	31
89	Drug-eluting stents and drug-eluting balloons are the best strategies to treat coronary in-stent restenosis. Evidence-Based Medicine, 2016, 21, 90-90.	0.6	2
90	Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 International Journal of Cardiology, 2016, 207, 168-176.	0.8	22

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
92	Risk stratification of patients undergoing medical therapy after coronary angiography. <i>European Heart Journal</i> , 2016, 37, 3103-3110.	1.0	12
93	Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2016, 32, 226-233.	0.8	51
94	Advances in dual therapy stenting. <i>Minerva Cardioangiologica</i> , 2016, 64, 204-15.	1.2	1
95	Complex PCI: When the going gets tough the tough gets going. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 11-12.	0.7	0
96	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1298-1310.	1.2	314
97	CABG surgery versus PCI in CAD surgery strikes again!. <i>Nature Reviews Cardiology</i> , 2015, 12, 75-77.	6.1	7
98	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
99	DAPT Duration After DES. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1103-1106.	1.2	28
100	Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 306-315.	1.6	12
101	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1036-1045.	1.2	344
102	Stable coronary artery disease: revascularisation and invasive strategies. <i>Lancet</i> , 2015, 386, 702-713.	6.3	152
103	Stroke prevention in valvular heart disease: from the procedure to long-term management. <i>EuroIntervention</i> , 2015, 14, W26-W31.	1.4	9
104	Usefulness of Baseline Activated Clotting Time-Guided Heparin Administration in Reducing Bleeding Events During Transfemoral Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 140-151.	1.1	20